A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
ConditionHealthy Participants
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorAstraZeneca
About this trial
The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.
Eligibility criteria
Qualifiers
Healthy male and female (of non-childbearing potential) participants with suitable veins for cannulation or repeated venipuncture at the Screening Visit.
All females must have a negative pregnancy test. Females of non-childbearing potential must be confirmed via post-menopausal status or documentation of irreversible surgical sterilization at the Screening Visit.
Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.
Have a body mass index between 18 and 32 kg/m2 inclusive and weigh at least 50 kg at Screening.
Disqualifiers
History of any clinically important disease or disorder which, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
Any abnormal laboratory values, vital signs, or any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
Trial design
Treatments tested in this trial
- AZD3974
- Placebo
Treatment groups
176 Participants
are divided into 28 treatment groups28
Treatment groupsSee each treatment group below.
Sponsors and collaborators
AstraZeneca
Lead sponsor
Parexel
Collaborator
Source ClinicalTrials.gov